Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Market capitalization(2018-04-20)

$36.6 M

Type

Public

Waltham, US

Founded

2001

Size (employees)

17 (est)

Website

chiasmapharma.com

Chiasma was founded in 2001 and is headquartered in Waltham, US

Report incorrect company information

Key People/Management at Chiasma

Roni Mamluk

CEO

Dana Gelbaum

VP of BD and Supply Chain

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs

Asi Haviv

VP of Clinical Development

Lillian Kuan

Alumni Advisory Committee Board Member

Report incorrect company information

Chiasma Office Locations

Chiasma has offices in Ness Ziona and Waltham

Waltham, US (HQ)

250 275 Wyman St

Ness Ziona, IL

5 Golda Me'ir St

Show all (2)

Report incorrect company information

Chiasma Financials and Metrics

Chiasma Financials

Summary

USD
Net income (FY, 2017)	(26.8 m)
EBIT (FY, 2017)	(28.1 m)
Market capitalization (20-Apr-2018)	36.6 m
Cash (31-Dec-2017)	14.6 m

Chiasma's current market capitalization is $36.6 m.

Income Statement

Annual

USD	FY, 2015	FY, 2016	FY, 2017
General and administrative expense			9.1 m
R&D expense	19 m	31.3 m	17.9 m
Operating expense total	19 m	31.3 m	28.1 m
EBIT	(35.4 m)	(61.3 m)	(28.1 m)

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
General and administrative expense						2.5 m	2.6 m
R&D expense	4.2 m	4.4 m	7.2 m	14.8 m	4.5 m	4.7 m	4.3 m
Operating expense total	7.6 m	9.2 m	17.2 m	26.7 m	9.4 m	7.1 m	6.9 m	6.9 m
EBIT	(7.6 m)	(9.2 m)	(17.2 m)	(26.7 m)	(9.4 m)	(7.1 m)	(6.9 m)	(6.9 m)

show all

Balance Sheet

Annual

USD	FY, 2015	FY, 2016	FY, 2017
Cash	41 m	37 m	14.6 m
Inventories	2.3 m	2.1 m
Current Assets	151.1 m	95.1 m	68.7 m
PP&E	676 k	683 k	193 k

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	63.3 m	140.9 m	39.1 m	30.5 m	28.5 m	19 m	18.4 m	12.1 m
Inventories								2.2 m
Current Assets	63.7 m	164.2 m	138.1 m	118.1 m	101.6 m	86.8 m	81.5 m	75.3 m
PP&E	570.6 k	573.5 k	1.7 m	2.6 m	2.4 m	646 k	607 k

show all

Cash Flow

Annual

USD	FY, 2015	FY, 2016	FY, 2017
Net Income	(35.9 m)	(61.1 m)	(26.8 m)
Depreciation and Amortization	201 k	433 k	152 k
Inventories	(1.7 m)	674 k
Accounts Payable	(161 k)	1.8 m	(1.6 m)

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017
Net Income	(12 m)	(21.4 m)	(17.2 m)	(43.8 m)	(9.4 m)	(7 m)	(6.8 m)
Depreciation and Amortization	98.6 k	146.2 k	59 k	153 k
Inventories							2.2 m
Accounts Payable	358.5 k	366 k	3.9 m	10.1 m	1.2 m	1.5 m	2 m